New antibody drug shows early promise for Hard-to-Treat blood cancers
NCT ID NCT05822843
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested a new drug called ESG206 in 13 adults with B-cell blood cancers that had not responded to standard treatments. ESG206 is an antibody designed to attach to a protein called BAFFR on cancer cells and help the immune system attack them. The main goals were to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ESG206 (an antibody that targets BAFFR on cancer cells)
- What this could lead to
- If it works, this could point toward a new treatment option for people with B-cell blood cancers who have run out of standard therapies.
- What could go wrong
- This is a very early, small Phase 1 trial with only 13 participants, so it is mainly checking safety and dosing. The drug may not shrink tumors or may cause side effects, and much larger studies are needed to know if it really helps.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
13 people
The number who actually took part.
- Started
-
Aug 2023
- Finished
-
Jan 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Willing and able to provide written informed consent for the trial. * Male or female and at least 18 years of age. * Subjects must have a histologically confirmed (or documented), incurable B-cell hematologic malignancy that had progressed despite standard of care therapy and for which there was no alternative therapy of proven benefit or no effective standard therapy is available or tolerable. * Measurable or evaluable Disease. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Subject must have adequate organ function. Exclusion Criteria: * Has had prior chemotherapy, targeted therapy, immunotherapy or any other agents used as systemic treatment for cancer, within 14 days before first dosing. * Had major surgery within 4 weeks before first dosing. * Had undergone an autologous stem cell transplant within 100 days before first dosing. * Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, or renal disease). * Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the investigational product or excipients. * Pregnant or breastfeeding women. * Unwillingness or inability to follow the procedures outlined in the protocol.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-cell lymphoid malignancies are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.